S2Medical AB (publ) announced that have entered into an exclusive distribution agreement with Provas Medical Ltd. for the sale of products in the Epiprotect series on the Turkish market. This three-year agreement marks a significant milestone for S2Medical's expansion and presence in the Middle East and will strengthen the company's position as a pioneer in wound healing. The agreement entails commitments from Provas Medical to place orders worth approximately 4.7 million Swedish kronor, provided that S2Medical's products are successfully registered in Turkey.

Provas Medical has a strong presence in Turkey and will play a key role in introducing the Epiprotect series to the Turkish market. S2Medical looks forward to a successful collaboration with Provas Medical and to improving the quality of life for patients through access to top-tier wound healing.